Drug Research

AvantGen collaborates with Tanabe Research Laboratories for successful completion of first cancer therapeutic antibody discovery program. AvantGen is accountable for producing novel…
Read More...

Confo Therapeutics announced that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small…
Read More...

Zytoprotec announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to PD-protec, the Company's peritoneal dialysis fluid for the…
Read More...

Carmot Therapeutics, announced that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA). As part of the agreement,…
Read More...

An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly…
Read More...

Carmot Therapeutics, announced that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA). As part of the agreement,…
Read More...

HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Boehringer Ingelheim to identify novel small molecule leads for targets of interest…
Read More...

Beactica, the Swedish drug discovery company, announced that it has been awarded 2 MSEK (~$240 000) by the Swedish Governmental Agency for Innovation Systems (Vinnova) to advance its…
Read More...

Arvinas LLC announced it has expanded its ongoing license agreement with Genentech, a member of the Roche Group, for the development of new therapeutics using Arvinas' novel PROTAC…
Read More...

Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases.…
Read More...

Ionis Pharmaceuticals and Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear…
Read More...

Quotient Clinical announced that it has signed an agreement with Nuformix Technologies Limited (a wholly owned subsidiary of Nuformix plc, ‘Nuformix’), to evaluate the clinical…
Read More...

Astellas Pharma Inc. and Universal Cells, Inc. announced that Astellas Institute for Regenerative Medicine ("AIRM") and Universal Cells have entered into an exclusive worldwide license…
Read More...

Takeda Pharmaceutical Company Limited and HemoShear Therapeutics announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic…
Read More...

Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative…
Read More...

Immatics announced the completion of its Series E financing, raising $58 million. The Series E funding was supported by existing investors including dievini Hopp Biotech holding,…
Read More...

Transgene and Randox have entered into a collaboration to combine their technologies and develop multifunctional oncolytic immunotherapies. Innovative oncolytic viruses (OVs) resulting…
Read More...

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ALUNBRIG® (brigatinib) 180…
Read More...

Medherant has signed an agreement with a Japanese transdermal patch company to evaluate the potential of its TEPI Patch technology to deliver a drug provided by the company.…
Read More...

Amgen and Simcere Pharmaceutical Group announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes…
Read More...